Overview and Scope
A nontuberculous mycobacterial (NTM) infection is an infectious disease caused by various species of mycobacteria other than mycobacterium tuberculosis, which is responsible for tuberculosis (TB). The role of nontuberculous mycobacterial (NTM) infections is primarily related to their impact on human health and their interaction with the immune system.

Sizing and Forecast
The nontuberculous mycobacterial infection market size has grown strongly in recent years. It will grow from $13.43 billion in 2023 to $14.25 billion in 2024 at a compound annual growth rate (CAGR) of 6.1%. The growth in the historic period can be attributed to improved diagnostics, aging population, cystic fibrosis awareness, immunosuppressive medications.

The nontuberculous mycobacterial infection market size is expected to see strong growth in the next few years. It will grow to $18.17 billion in 2028 at a compound annual growth rate (CAGR) of 6.3%. The growth in the forecast period can be attributed to antimicrobial drug development, increasing ntm awareness, advances in genetic research, telehealth and remote monitoring. Major trends in the forecast period include personalized treatment, regulatory focus, combination therapies, digital health tools.

To access more details regarding this report, visit the link:
https://www.thebusinessresearchcompany.com/report/nontuberculous-mycobacterial-infection-global-market-report

Segmentation & Regional Insights
The nontuberculous mycobacterial infection market covered in this report is segmented –
1) By Drug Class: Macrolides; Rifampin; Aminoglycoside; Other Drug Classes
2) By Route Of Administration: Oral; Parenteral; Other Routes
3) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies

North America was the largest region in the nontuberculous mycobacterial infection market in 2023. North America is expected to be the fastest-growing region in the forecast period. The regions covered in nontuberculous mycobacterial infection market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Intrigued to explore the contents? Secure your hands-on sample copy of the report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=13020&type=smp

Major Driver Impacting Market Growth
The rising prevalence of chronic obstructive pulmonary disease (COPD) is expected to propel the growth of the nontuberculous mycobacterial infection market going forward. Chronic obstructive pulmonary disease (COPD) is a chronic respiratory condition characterized by persistent and often progressive lung airflow limitation. Nontuberculous mycobacterial (NTM) infections in patients with COPD are associated with a more significant decline in forced expiratory volume in one second (FEV1) and an increased exacerbation rate. COPD may weaken the immune system and damage the lung tissue, making it easier for NTM bacteria to infect the lungs. For instance, in March 2023, according to a report published by The Scottish Public Health Observatory (ScotPHO), a Scotland-based public health body, COPD rates began to climb between 2021 and 2022, with male rates increasing from 83.2 to 97.6 per 100,000 persons while female rates increased from 72.6 to 97.3. Therefore, the rising prevalence of chronic obstructive pulmonary disease (COPD) drives the growth of the nontuberculous mycobacterial infection market.

Key Industry Players
Major players in the nontuberculous mycobacterial infection market are Pfizer Inc., Johnson & Johnson, F. Hoffman La Roche AG, Merck & Co. Inc., AbbVie Inc., Bayer AG, Novartis AG, Sanofi S.A., Bristol Myers Squibb, AstraZeneca PLC, Abbott Laboratories, GlaxoSmithKline PLC, Takeda Pharmaceutical Company, Eli Lilly and Company, C.H. Boehringer Sohn AG & Co. KG, Teva Pharmaceutical Industries Ltd., Mylan N.V., Astellas Pharma Inc., Vertex Pharmaceuticals Inc., Sun Pharmaceutical Industries Ltd., Horizon Therapeutics PLC, Lupin Limited, BioMarin Pharmaceutical Inc., Ionis Pharmaceuticals Inc., Insmed Incorporated, Paratek Pharmaceuticals Inc., Spero Therapeutics Inc., Aradigm Corporation, Dauntless Pharmaceuticals Inc., Validus Pharmaceuticals LLC.

The nontuberculous mycobacterial infection market report table of contents includes:
1. Executive Summary
2. Nontuberculous Mycobacterial Infection Market Characteristics
3. Nontuberculous Mycobacterial Infection Market Trends And Strategies
4. Nontuberculous Mycobacterial Infection Market - Macro Economic Scenario
5. Global Nontuberculous Mycobacterial Infection Market Size and Growth
6. Nontuberculous Mycobacterial Infection Market Segmentation
7. Nontuberculous Mycobacterial Infection Market Regional And Country Analysis
.................
34. Key Mergers And Acquisitions In The Nontuberculous Mycobacterial Infection Market
35. Nontuberculous Mycobacterial Infection Market Future Outlook and Potential Analysis
36. Appendix

List Of Tables :
Table 1: Global Historic Market Growth, 2018-2023, $ Billion
Table 2: Global Forecast Market Growth, 2023-2028F, 2033F, $ Billion
Table 3: Global Nontuberculous Mycobacterial Infection Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
Table 4: Global Nontuberculous Mycobacterial Infection Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
Table 5: Global Nontuberculous Mycobacterial Infection Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
...............
Table 74: Pfizer Inc. Financial Performance
Table 75: Johnson & Johnson Financial Performance
Table 76: F. Hoffman La Roche AG Financial Performance
Table 77: Merck & Co. Inc. Financial Performance
Table 78: AbbVie Inc. Financial Performance

Explore the trending research reports from TBRC:
https://topprnews.com/medical-specialty-bags-market-demand/
https://goodprnews.com/switchgear-monitoring-system-market-new-trends/

Learn About Us:
The Business Research Company is a market intelligence firm that pioneers in market, company, and consumer research. TBRC’s specialist consultants are located globally and are experts in a wide range of industries that include healthcare, manufacturing, financial services, chemicals, and technology. The firm has offices located in the UK, the US, and India, along with a network of proficient researchers in 28 countries.

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model